> Pascal Biosciences Inc. biopharmaceutical company <
About
Pascal Biosciences Inc. (TSXV:PAS, FSE:6PB.F) is a biopharmaceutical company founded in 2013 to advance technology licensed from the University of British Columbia. We create additional value with programs licensed from other organizations and with our in-house discovery research. Cancer is our primary focus. Strategically, we aim to leverage our innovative technologies and experienced leadership and scientific team to develop new, effective therapeutics that will change the lives of patients.
Pascal has a strong development pipeline. Our leading cannabinoid portfolio includes a Cannabinoid for COVID-19; PAS-403, a small molecule therapeutic advancing into clinical trials for the treatment of glioblastoma; and PAS-393, an immuno-stimulatory molecule designed to enhance efficacy of checkpoint inhibitors. In addition, we are developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas.